Status:
UNKNOWN
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Lead Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
7-60 years
Phase:
PHASE3
Brief Summary
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral...
Eligibility Criteria
Inclusion
- Having signed informed consent
- Diagnosis was based on the French-American-British (FAB) and WHO criteria.
- Age ≥ 7 years old
- Age \< 60 years old
Exclusion
- Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01484171
Start Date
August 1 2011
End Date
December 1 2017
Last Update
July 13 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Hospital of the Chinese Academy of Military Medical Science
Beijing, Beijing Municipality, China, 100071